Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Drug and alcohol dependence - 1 Nov 2015

McRae-Clark Aimee L, Baker Nathaniel L, Gray Kevin M, Killeen Therese K, Wagner Amanda M, Brady Kathleen T, DeVane C Lindsay, Norton Jessica

Abstract excerpt

BACKGROUND: The purpose of this study was to evaluate the efficacy of buspirone, a partial 5-HT1A agonist, for treatment of cannabis dependence. METHODS: One hundred seventy-five cannabis-dependent adults were randomized to receive either up to 60mg/day of buspirone (n=88) or placebo (n=87) for 12 weeks combined with a brief motivational enhancement therapy intervention and contingency management to encourage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cannabinoids
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Marijuana Abuse

Share to Motivation

Share to Patient Compliance

Share to Psychotherapy

Share to Receptor, Serotonin, 5-HT1A

Share to Serotonin Receptor Agonists

Source

Open in PubMed Open full text

Identifiers

PMID: 26386827
DOI: 10.1016/j.drugalcdep.2015.08.013
PMCID: PMC4633378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.PMID 26386827Read ↗

Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of ActionSemantic proximity Read ↗

A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.Semantic proximity Read ↗

Pharmacological Smoking Cessation Interventions in People with Cannabis, Opioid, or Stimulant Use Disorders: A Systematic ReviewSemantic proximity Read ↗

A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two yearsSemantic proximity Read ↗

Prevalence of Cannabis Use Disorder: A Meta-Analysis of Population SurveysSemantic proximity Read ↗

Cannabis and Anhedonia in Psychiatric Disorders: A Systematic ReviewSemantic proximity Read ↗

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Semantic proximity Read ↗

Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.Semantic proximity Read ↗

The Effect of Music Therapy on Substance Use Disorder Patients in the Rehabilitation StageSemantic proximity Read ↗

Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a translational crossover randomized trialSemantic proximity Read ↗

Cannabidiol (CBD) does not reduce cocaine reward or self-administration in a mouse model of schizophrenia genetic susceptibility.Semantic proximity Read ↗

Ten-Year Outcomes of Medical Cannabis for Chronic Low Back Pain: Opioid Reduction, Pain Relief, and Functional Improvement in 1,000 PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.